Catrin Pritchard
Personal Details
Deputy Director of Leicester Cancer Research Centre
Tel: 0116 229 7061
Email: cap8@le.ac.uk
Career
- 1983-1987: PhD at the Imperial Cancer Research Fund.
- 1987-1990: Postdoctoral Fellow, University of California, San Francisco, USA.
- 1991-1995: Postdoctoral Fellow, DNAX Research Institute, Palo Alto, California, USA.
- 1995-2003: Royal Society Research University Research Fellow, University of Leicester.
- 2003-2004: Lecturer, Department of Biochemistry, University of Leicester.
- 2004-2009: Reader, Department of Biochemistry, University of Leicester.
- 2009: Professor of Cancer Biochemistry, University of Leicester.
- 2010-2015: Royal Society-Wolfson Research Merit Award Holder
- 2014-2017: Science Director Cancer Research UK Leicester Centre
- 2014-2018: Head of Leicester Cancer Research Centre, University of Leicester
- 2018-present Deputy Director Cancer Research Centre, University of Leicester
Publications
Recent publications (since 2010)
Research
Signal transduction through the RAF-MEK-ERK pathway
- Feedback control of the RAF-MEK-ERK pathway in normal and cancer cells.
- Subcellular localisation of wild-type and oncogenic RAF isoforms.
- Role of phosphorylation in control of RAF activity and RAF protein stability.
RAS and RAF-driven tumour development
- RAS and RAF conditional knockin mouse models for modeling human cancer initiation and progression focusing on lung adenocarcinoma and colorectal cancer models.
- Investigation of the role of Glycogen Synthase Kinase 3 (GSK3) in V600EBRAF-driven colorectal cancer development using mouse models.
- Characterisation of the microenvironment of premalignant lesions driven in the lung using mouse models and human tumour tissue microarrays.
- Cholesterol metabolism in tumour associated macrophages (TAMs) and targeting of TAMs by cholesterol modulating agents.
Novel ex vivo tumour explant platform for drug discovery and development
- Optimisation of conditions for ex vivo tumour explant culture for a range of human cancers
- Application of digital pathology to the characterisation and quantitation of tumour explant drug responses.
- Derivation of patient-relevant data on drug responses correlated with predictive and pharmacodynamic biomarkers.
- Collaborations and contracts with commercial partners to extend the application of the explant platform to the drug development pipeline.